Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications Beyond Atopic Dermatitis

    September 2024 in “ Life ”
    George Mitroi, George F. Mitroi, Oana Maria Ică … Mihaela Roxana Mitroi
    Studysummary This review found that, among 103 patients treated off-label with abrocitinib for conditions beyond atopic dermatitis, favorable clinical outcomes were reported for most cases, except one isolated case involving erythematotelangiectatic rosacea.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on mdpi.com →
    Discuss this study in the Community →

    Research cited in this study 7

    1. Successful Treatment of Alopecia Universalis With Abrocitinib: A Case Report Journal of Dermatological Treatment · 2023
    2. Effective Treatment of Refractory Alopecia Areata in Pediatric Patients With Oral Abrocitinib Journal of cosmetic dermatology · 2023
    3. The Janus Kinase 1 Inhibitor Abrocitinib for the Treatment of Oral Lichen Planus JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2023
    4. A Case of Atopic Dermatitis with Alopecia Universalis in a Patient Treated with Abrocitinib JAAD case reports · 2022
    5. Interventions for Chronic Pruritus of Unknown Origin Cochrane Database of Systematic Reviews · 2020
    6. Alopecia Areata Is Characterized by Dysregulation in Systemic Type 17 and Type 2 Cytokines, Which May Contribute to Disease-Associated Psychological Morbidity British journal of dermatology/British journal of dermatology, Supplement · 2019
    7. Simultaneous Improvement of Alopecia Universalis and Atopic Dermatitis in a Patient Treated with a JAK Inhibitor JAAD case reports · 2018